DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:

  • Non-Hodgkin's lymphoma (NHL) of 1 of the following subtypes:

    • Precursor B-cell or precursor T-cell NHL

      • Lymphoblastic lymphoma in second or greater complete remission (CR) or first or subsequent PR OR lymphoblastic lymphoma in first CR (CR1) with high-risk features (i.e., stage IV disease, lactic dehydrogenase [LDH] > 2 times normal, or 2 or more extranodal sites)

    • Mature B-cell lymphoma, including any of the following:

      • Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) in ≥ CR1 with molecularly negative disease* NOTE: *Patients in CR with molecularly positive disease or in PR are not eligible
      • Follicular lymphoma in ≥ CR1 or first PR (PR1) (if treatment is delayed until clinically required) OR in ≥ second CR/PR (CR2/PR2) and was treated at diagnosis (without clinical symptoms necessitating treatment, such as B symptoms, bulky disease, marrow or other organ compromise)
      • Diffuse large B-cell lymphoma in ≥ CR2 or ≥ PR1 OR in CR1 with high-intermediate or high International Prognostic Index (IPI) score (≥ 2 for age-adjusted IPI or ≥ 3 for IPI) at diagnosis
      • Mantle cell lymphoma in first or greater CR or PR
      • Burkitt's/Burkitt's-like lymphoma in CR1 after receiving initial therapy (except patients with localized** lymphoma) OR in PR and failed to achieve CR NOTE: **Localized (stage I or Ziegler stage A) disease allowed only if failed to achieve CR1 or in relapse

    • Mature T-cell lymphoma, including any of the following:

      • Primary T-cell lymphoma not otherwise specified, angioimmunoblastic lymphoma, or ALK-positive anaplastic large cell lymphoma that was previously treated with initial therapy (may or may not be in CR)
      • Mycosis fungoides/Sezary syndrome in ≥ CR2/PR2
    • No resistant or refractory lymphoma (i.e., no partial remission [PR] after treatment with up to 3 courses of combination chemotherapy)

  • Hodgkin's lymphoma (HL) meeting the following criteria:

    • Failed prior therapy

    • No resistant disease (initial disease or at relapse)

      • Resistant disease is defined as failing to achieve an objective PR to 3 courses of combination noncross-resistant chemotherapy
    • Patients with stage I or II disease treated with primary radiation must have failed (no CR OR progression after CR) ≥ 1 salvage combination chemotherapy regimen
    • Patients with advanced (stage III or IV) disease must have failed a doxorubicin hydrochloride-containing regimen (e.g., doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine [ABVD]) or an alternative noncross-resistant chemotherapy regimen (e.g., mechlorethamine, vincristine, procarbazine hydrochloride, and prednisone [MOPP])

    • High-risk disease allowed, including any of the following:

      • Failed to achieve CR with initial combination chemotherapy
      • Bulky disease after initial therapy (chemotherapy or radiation), defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., gallium or positron-emission tomography [PET] scan positive; high LDH; enlarging mass on serial x-rays or biopsy-positive)
• Bone marrow cellularity > 20% with < 10% involvement with tumor
• History of CNS involvement by lymphoma or relapsed primary CNS lymphoma allowed
• Active CNS disease allowed if standard treatment for CNS lymphoma was completed and there is no evidence of progressive CNS disease at study entry

• Patients with lymphoma who are HIV positive are eligible as long as all of the following criteria are met:

  • Must be on maximally active anti-HIV regimen to control disease
  • CD4+ ≥ 50/μL

  • HIV RNA viral load ≤ 100,000 copies/mL on each sample 4 weeks apart

    • Most recent level must have been within the past month
• No chemotherapy-resistant disease
• Ineligible for any higher priority transplant protocols

PATIENT CHARACTERISTICS:

• Karnofsky performance status 90-100% (70-100% if poor performance status is related to lymphoma)
• Life expectancy > 8 weeks
• WBC > 2,500/mm³
• Absolute neutrophil count > 1,500/mm³
• Platelet count > 100,000/mm³ (without transfusion)
• Hemoglobin > 8 g/dL (without transfusion)
• Creatinine ≤ 2.0 mg/dL OR creatinine clearance > 50 mL/min
• Bilirubin ≤ 2.0 mg/dL
• AST< 5 times upper limit of normal (ULN)
• Alkaline phosphatase < 5 times ULN
• No uncontrolled cardiac disease, including unstable angina, decompensated congestive heart failure, or arrhythmia
• LVEF > 45% by MUGA
• No significant obstructive airway disease (FEV_1 ≥ 50%)
• Corrected DLCO > 50% of predicted
• No severe prior or ongoing chronic liver disease
• No serious uncontrolled infection
• No other evidence of serious organ dysfunction that is not attributable to tumor
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

• Hepatitis B carriers allowed

  • No rituximab as part of study chemotherapy mobilization

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 14 days since prior epoetin alfa
• At least 21 days since prior darbepoetin alfa or pegfilgrastim
• At least 10 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)